Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Omission of breast surgery after neoadjuvant systemic therapy (NST) in select patients with invasive breast cancer may be feasible.

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

For patients with breast cancer, the brain functional network shows a shift toward a more randomized pattern after neoadjuvant chemotherapy.

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

Omission of endocrine therapy in estrogen receptor (ER)-low early breast cancer had a significant association with worse ...

Ideaya Biosciences (IDYA) announced a FDA Type D meeting on the Phase 3 registrational trial design that will assess the safety and efficacy of ...

For a patient with locally advanced lung cancer, the benefits of neoadjuvant chemoimmunotherapy should stand regardless of the destination of local therapy. The responses to chemoimmunotherapy that we ...

CEL-SCI (CVM) announced that a study titled “Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies” by Li ...